Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Spero Therapeutics Q2 EPS $(0.03) Beats $(0.38) Estimate, Sales $14.189M Up From $10.197M YoY

Author: Benzinga Newsdesk | August 12, 2025 03:03pm
Spero Therapeutics (NASDAQ:SPRO) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.38) by 92.11 percent. This is a 90.91 percent increase over losses of $(0.33) per share from the same period last year. The company reported $14.189 million in sales this quarter. This is a 39.15 percent increase over sales of $10.197 million the same period last year.

Posted In: SPRO


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist